Injured and fibrotic lung tissue

Injured and fibrotic lung tissue is a pathological state characterized by the progressive and irreversible replacement of healthy alveolar structures with dense, collagen-rich extracellular matrix (ECM). This process is driven by persistent epithelial injury, which triggers the activation of myofibroblasts and the release of pro-fibrotic cytokines such as Transforming Growth Factor-beta (TGF-beta) and Platelet-Derived Growth Factor (PDGF) (King et al., 2011, The Lancet). As the tissue becomes increasingly scarred, its compliance decreases, leading to restrictive lung physiology and severely impaired oxygen diffusion. While not a single molecular target, this tissue environment is the primary focus of anti-fibrotic drug development, with current therapies like nintedanib and pirfenidone aiming to modulate the signaling pathways that govern fibroblast proliferation and ECM deposition (Richeldi et al., 2014, New England Journal of Medicine). The complexity of the fibrotic niche, which includes altered mechanical stiffness and hypoxic zones, presents significant challenges for drug delivery and efficacy. Consequently, research often focuses on identifying specific molecular drivers within this tissue to develop more localized and effective interventions (Martinez et al., 2017, Nature Reviews Disease Primers).

Other names

Pulmonary fibrosisLung scarringFibrotic lung parenchymaInterstitial lung disease tissueFibrotic lung microenvironment

Inhibition of pro-fibrotic growth factor receptors (VEGFR, PDGFR, FGFR) and reduction of TGF-beta-induced collagen synthesis to mitigate fibroblast activation and tissue remodeling (Noble et al., 2011, The Lancet).